Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and complete the Phase I study of CBX‑250, the company said. CEO Briggs Morrison told BioXconomy the financing will support CBX‑250’s pivotal early work in relapsed or refractory myeloid malignancies, and the company has nominated a second candidate, CBX‑663. The T‑Bolt approach engineers antibodies that mimic T‑cell receptors to recognize peptide fragments presented by HLA complexes, enabling access to intracellular tumor targets that conventional antibodies cannot see. Crossbow said proceeds will fund clinical development and pipeline expansion, including an IND filing planned in 2026 for additional programs.